Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. - Wikidata - awgldk - TriplyDB

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

http://www.wikidata.org/entity/Q34284684

about

The differential diagnosis of food intolerance Pharmacological treatment options for mast cell activation disease Hypotension, Syncope, and Fever in Systemic Mastocytosis without Skin Infiltration and Rapid Response to Corticosteroid and Cyclosporin: A Case Report.Mastocytosis.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Imatinib: a breakthrough of targeted therapy in cancer.Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis Diagnosis and treatment of mast cell disorders: practical recommendations.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.How I treat hypereosinophilic syndromes.Signal transduction and chemotaxis in mast cells Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat.A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33)Mastocytosis and systemic sclerosis: a clinical association Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive.Therapeutic targeting of c-KIT in cancer.Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Indolent systemic mastocytosis limited to the bone: a case report and review of the literature.Mastocytosis: update on pharmacotherapy and future directions.Gene of the month: KIT.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.Mastocytosis: from a Molecular Point of View.Targeted Treatment Options in Mastocytosis.Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.Systemic Mastocytosis Causing Refractory Pruritus in a Liver Disease Patient.Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

P2860

Q24646927-7B441F22-97D8-4DC5-859B-CECDCCA2CDC0 Q26748784-264663C6-39DF-41DC-A0B0-3EE735320472 Q33159586-65CFD867-44C2-4FD3-853A-670E9F4582D9 Q33163541-280AF546-B960-48BC-AFE5-F4B8D0683628 Q33423072-C9E540AA-6316-4F12-B971-27F89E193DAD Q33747261-539DE3BA-1527-474C-89CB-953C0846F2E3 Q34284691-6FFBE3E9-64B7-497F-BE8C-FDD432B9C060 Q35021196-6DE4B7BC-3FB8-45F2-A753-A82791BF1E21 Q35117747-068BDBA5-9F0D-4D7C-AFE3-24827AF469AE Q35865095-1D31D0EB-C9C4-4821-BCBD-98F62D634075 Q36000858-AE514741-C5CA-4F50-A1AA-ADFADE0B2198 Q36240848-F2106124-5BA9-4038-87B2-1E742B2CD31D Q36440066-E4769E15-8FEA-4CE6-9E46-1D544B1EA0AF Q36487624-A2727C00-D322-4726-A327-E2E577428790 Q36730397-D88F4A3D-A22C-4564-902F-C259B86A165A Q37048439-2C1B96AE-8FD8-4B69-985D-E8E5DB8B640E Q37239587-D395C30E-CF44-4007-8A64-D6AD35C51C3C Q37331016-F9E29494-BD27-4EBC-B7D6-468BC8CE720E Q37450689-4FB60E59-E85B-40F9-97C3-9FAEDFB94D9F Q37854888-88ED8172-493E-4EB9-A8A1-A3E89C4E9D3D Q37892475-8AF3B858-3D8C-4CE2-AFC3-255D1D8FC38B Q37992835-6FE66E0D-46D5-4D4F-A79C-EB738791E165 Q38045311-F3A5DA43-9542-4418-8529-8BDB7007C7D8 Q38057806-D1624E33-AB22-4A9C-AF20-9CE26AC26473 Q38110527-A90BC17F-F170-4D5B-83FA-2B2438709B24 Q38125573-7ACC61C9-7D04-446E-919E-9FD963A8EF00 Q38138597-00A83985-D9CF-41ED-952C-EE77F23D83C2 Q38541920-7B9C21C8-2BF0-4688-B530-2CBE9624D324 Q38661465-133210F7-E062-40E6-98ED-776EE6DF269E Q38777126-1438B687-ACBD-4E34-B549-65A71C7A0BAE Q38905860-3284866C-36B3-4A5B-A72F-33848695A684 Q38909315-DBA33185-89E1-43E7-992D-66E4AEE9B359 Q39267824-E43C1F08-B4F1-4B7F-AF69-905E747DFF5F Q39446801-7453051E-CA79-4DC0-A6C4-0E023679F733 Q41061871-AEEFDB53-27BB-4D7F-B5EE-107061165E62 Q42081445-3C58D2FF-C4EB-4DF6-B06A-612B07CBA697 Q42362452-914E352F-3E15-4F83-BC2F-67A7506A0BAB Q45058347-DAE9A497-0BE5-47D2-9928-24F3217BB836 Q47161255-E0BB3310-A929-49DF-AC0F-59F21761E436 Q51498353-1ED232ED-32CE-40BE-A634-561B3104B01B

P2860

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

http://www.wikidata.org/entity/Q34284684

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@ast

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@en

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@nl

type

label

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@ast

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@en

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@nl

prefLabel

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@ast

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@en

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@nl

P1433

Q34284684-BE74D2A3-ABB6-466E-84D7-73AABBD184BD

P1476

Q34284684-C3AC9FFE-4291-41D3-84A5-A5843D642614

P2093

Q34284684-02923445-C808-4A43-A1C8-FE2FB375390B

Q34284684-06CC220B-F033-4E0F-894F-B06A2BB1248A

Q34284684-084968FA-007A-4417-AA7C-9BD4C71193FE

Q34284684-6225CE15-678B-4103-BA10-90E247B0DD96

Q34284684-68C9908F-E1D7-4A90-8143-FAEE05732544

P2860

Q34284684-0485F5F8-48BC-40EC-B0A5-8D58DEB613ED

Q34284684-1E51426A-1138-4186-9F86-8A876FA05C3C

Q34284684-23095E5A-5EF1-4BA8-9FBE-88D8C176E44E

Q34284684-3B1105D9-CA1B-436F-922A-7A595B29EDCE

Q34284684-50EBA69F-ED56-4ECD-AE64-9DF5E58582DD

Q34284684-582CBE06-19D2-4529-9BB7-22A2F1ACB5FE

Q34284684-9BE7389A-B010-4749-8B04-5A7F9FD67FB2

Q34284684-9C01B316-A642-4033-8E0C-77923138E581

Q34284684-ACB426B3-E32A-4872-AE30-408805A3E9D2

Q34284684-D7D74FF4-1E8F-48CC-904A-5315BC601565

P304

Q34284684-52CDC879-89BB-48E8-9996-5CFDD11A5BC6

P31

Q34284684-A9172124-F2B5-4B2B-B453-0574F7DE91EF

P356

Q34284684-F1FDE0BE-8014-4A60-A9A0-5CDDB94A6E64

P433

Q34284684-4ACB775D-E8D3-4D62-AED6-C8BFB00A8772

P478

Q34284684-B5F90FAE-7460-4150-A0CF-910F5735B209

P50

Q34284684-16ACF3DF-A4AC-4AA6-B65A-FE6EA575491B

Q34284684-5FE39867-DC70-4C01-B0AC-F3BA62FD4C28

Q34284684-747A16FB-8838-42AE-BDDB-6D53ADA2AA61

P577

Q34284684-AE8B973C-2BE1-47FC-8D51-71822B9F8D34

P698

Q34284684-38913C70-8FF8-40AE-92B7-4961FF3E6926

P932

Q34284684-0DF318C3-DBB3-4592-B61A-D896A9000E68

P356

J.LEUKRES.2008.12.020

P1433

Leukemia Research

P1476

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Arturo Vega-Ruiz

http://www.w3.org/2001/XMLSchema#string

Matjaz Sever

http://www.w3.org/2001/XMLSchema#string

Raja Luthra

http://www.w3.org/2001/XMLSchema#string

Taghi Manshouri

http://www.w3.org/2001/XMLSchema#string

P2860

Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders

Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.

Mastocytosis: state of the art.

Novel approaches in the treatment of systemic mastocytosis.

Imatinib mesylate in the treatment of hematologic malignancies.

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

P304

1481-1484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2008.12.020

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

Srdan Verstovsek

P577

2009-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19193436

http://www.w3.org/2001/XMLSchema#string

P932

4184059

http://www.w3.org/2001/XMLSchema#string